Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PROTHENA CORP PUBLIC LTD COPRTA · Entity 2375 | Chief Strategy Officer and CFO | July 28, 2026 | July 31, 2026 |
| Rain Oncology Inc.RAIN · Entity 94695 | Director | January 26, 2024 | January 26, 2024 |
| Sierra Oncology, Inc.SRRA · Entity 125698 | Director | June 11, 2019 | June 12, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PROTHENA CORP PUBLIC LTD CO
Report date July 28, 2026 · Filed July 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, par value $0.01 per shareSEC Table I · non-derivative | Direct | 40,205 |
Ending reported balance
After 2026-07-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-07-28 · Exercise / conversion · Acquired 57,000 · Balance 97,205 F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Ordinary Shares upon vesting. Row 2 · 2026-07-28 · Disposition to issuer · Disposed 57,000 · Balance 40,205 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-07-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-07-28 · Exercise / conversion · Disposed 57,000 · Balance 0 F2: These RSUs reported in Table II were granted to the Reporting Person on July 28, 2025 as part of an aggregate award of 95,000 RSUs and initially reported in Table I of the Form 4 filed on July 30, 2025, because they were solely settleable in shares at the time of grant. These RSUs are being moved to Table II as of this Form 4. F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Ordinary Shares upon vesting. F3: These RSUs reported in Table II are fully vested as of July 28, 2026 (the one-year anniversary of the grant date). The remainder of the 95,000 RSUs reported in Table I (38,000 RSUs) are subject to vesting. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Ordinary Shares upon vesting.
F2: These RSUs reported in Table II were granted to the Reporting Person on July 28, 2025 as part of an aggregate award of 95,000 RSUs and initially reported in Table I of the Form 4 filed on July 30, 2025, because they were solely settleable in shares at the time of grant. These RSUs are being moved to Table II as of this Form 4.
F3: These RSUs reported in Table II are fully vested as of July 28, 2026 (the one-year anniversary of the grant date). The remainder of the 95,000 RSUs reported in Table I (38,000 RSUs) are subject to vesting.
Rain Oncology Inc.
Report date January 26, 2024 · Filed January 26, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.95 | Direct | 0 |
Reported balance
After 2024-01-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-01-26 · Disposition to issuer · Disposed 13,890 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.13 | Direct | 0 |
Reported balance
After 2024-01-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-01-26 · Disposition to issuer · Disposed 42,596 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.21 | Direct | 0 |
Reported balance
After 2024-01-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-01-26 · Disposition to issuer · Disposed 35,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.44 | Direct | 0 |
Reported balance
After 2024-01-26 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-01-26 · Disposition to issuer · Disposed 20,000 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.
Sierra Oncology, Inc.
Report date June 11, 2019 · Filed June 12, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.66 · Expires 2029-06-11 | Direct | 30,000 |
Reported balance
After 2019-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-11 · Grant · Acquired 30,000 · Balance 30,000 F1: The option vests as to 8.333% of the total shares monthly, beginning on July 11, 2019, with 100% of the total shares vested and exercisable on June 11, 2020, subject to the reporting person's provision of service to the issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests as to 8.333% of the total shares monthly, beginning on July 11, 2019, with 100% of the total shares vested and exercisable on June 11, 2020, subject to the reporting person's provision of service to the issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 21, 2022 Filed Sep 24, 2022 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $6.73 | $0.00 |
DisclosureSEC source: 0001140361-22-034587 · form4.xml · derivative · entry 3 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Ordinary Shares · 10,000 shares Expires 2023-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option was granted on April 1, 2013 and all shares subject to the option were fully vested and exercisable. The option will expire in approximately six months and be forfeited to the extent it is not exercised on or prior to March 31, 2023. F4 · balance_after: The Reporting Person holds options that give him the right to acquire an aggregate of 913,837 shares at exercise prices ranging from $6.73 to $32.45, of which 725,087 are currently exercisable, and 188,750 are currently unexercisable but vest over time, subject to the Reporting Person's continued employment with the Issuer on each applicable vesting date of each option award. Certain of these options are subject to the Court Order. Read SEC document |
| September 21, 2022 Filed Sep 24, 2022 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 10,000 | $30.75 | $307,496.00 |
DisclosureSEC source: 0001140361-22-034587 · form4.xml · nonDerivative · entry 2 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,200 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in connection with a court stipulation and proposed order regarding the separation of assets ("Court Order") in anticipation of a potential divorce settlement agreement. F2 · price: The transaction was executed in multiple trades in prices ranging from $30.47 to $30.875, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| September 21, 2022 Filed Sep 24, 2022 01:30 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 10,000 | $6.73 | $67,300.00 |
DisclosureSEC source: 0001140361-22-034587 · form4.xml · nonDerivative · entry 1 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 24, 2022 Filed Aug 27, 2022 01:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $6.73 | $0.00 |
DisclosureSEC source: 0001567619-22-016737 · doc1.xml · derivative · entry 3 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Ordinary Shares · 10,000 shares Expires 2023-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option was granted on April 1, 2013 and all shares subject to the option were fully vested and exercisable. The option will expire in approximately seven months and be forfeited to the extent it is not exercised on or prior to March 31, 2023. F4 · balance_after: The Reporting Person holds options that give him the right to acquire an aggregate of 923,837 shares at exercise prices ranging from $6.73 to $32.45, of which 733,107 are currently exercisable, and 190,730 are currently unexercisable but vest over time, subject to the Reporting Person's continued employment with the Issuer on each applicable vesting date of each option award. Certain of these options are subject to the Court Order. Read SEC document |
| August 24, 2022 Filed Aug 27, 2022 01:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 10,000 | $30.17 | $301,672.00 |
DisclosureSEC source: 0001567619-22-016737 · doc1.xml · nonDerivative · entry 2 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,200 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in connection with a court stipulation and proposed order regarding the separation of assets ("Court Order") in anticipation of a potential divorce settlement agreement. F2 · price: The transaction was executed in multiple trades in prices ranging from $29.71 to $30.70, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 24, 2022 Filed Aug 27, 2022 01:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 10,000 | $6.73 | $67,300.00 |
DisclosureSEC source: 0001567619-22-016737 · doc1.xml · nonDerivative · entry 1 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,200 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 22, 2022 Filed Jul 23, 2022 01:37 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,320 | $0.00 Strike: $6.73 | $0.00 |
DisclosureSEC source: 0001567619-22-014382 · doc1.xml · derivative · entry 11 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Ordinary Shares · 7,320 shares Expires 2023-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option was granted on April 1, 2013 and all shares subject to the option were fully vested and exercisable. The option will expire in approximately eight months and be forfeited to the extent it is not exercised on or prior to March 31, 2023. F7 · balance_after: The Reporting Person holds options that give him the right to acquire an aggregate of 933,837 shares at exercises prices ranging from $6.73 to $32.45, of which 733,253 are currently exercisable, and 200,584 are currently unexercisable but vest over time, subject to the Reporting Person's continued employment with the Issuer on each applicable vesting date of each option award. Certain of these options are subject to the Court Order. Read SEC document |
| July 22, 2022 Filed Jul 23, 2022 01:37 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 7,320 | $32.55 | $238,253.56 |
DisclosureSEC source: 0001567619-22-014382 · doc1.xml · nonDerivative · entry 8 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,200 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in connection with a court stipulation and proposed order regarding the separation of assets ("Court Order") in anticipation of a potential divorce settlement agreement. F5 · price: The transaction was executed in multiple trades in prices ranging from $32.15 to $32.91, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| July 22, 2022 Filed Jul 23, 2022 01:37 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 7,320 | $6.73 | $49,263.60 |
DisclosureSEC source: 0001567619-22-014382 · doc1.xml · nonDerivative · entry 7 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,520 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 21, 2022 Filed Jul 23, 2022 01:37 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,560 | $0.00 Strike: $6.73 | $0.00 |
DisclosureSEC source: 0001567619-22-014382 · doc1.xml · derivative · entry 10 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,320 Underlying: Ordinary Shares · 20,560 shares Expires 2023-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option was granted on April 1, 2013 and all shares subject to the option were fully vested and exercisable. The option will expire in approximately eight months and be forfeited to the extent it is not exercised on or prior to March 31, 2023. Read SEC document |
| July 21, 2022 Filed Jul 23, 2022 01:37 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 5 | $33.69 | $168.45 |
DisclosureSEC source: 0001567619-22-014382 · doc1.xml · nonDerivative · entry 6 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,200 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in connection with a court stipulation and proposed order regarding the separation of assets ("Court Order") in anticipation of a potential divorce settlement agreement. Read SEC document |
| July 21, 2022 Filed Jul 23, 2022 01:37 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 20,555 | $32.64 | $670,925.48 |
DisclosureSEC source: 0001567619-22-014382 · doc1.xml · nonDerivative · entry 5 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,205 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in connection with a court stipulation and proposed order regarding the separation of assets ("Court Order") in anticipation of a potential divorce settlement agreement. F4 · price: The transaction was executed in multiple trades in prices ranging from $32.28 to $32.895, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| July 21, 2022 Filed Jul 23, 2022 01:37 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 20,560 | $6.73 | $138,368.80 |
DisclosureSEC source: 0001567619-22-014382 · doc1.xml · nonDerivative · entry 4 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,760 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 20, 2022 Filed Jul 23, 2022 01:37 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionStock Option (Right to Buy) · Derivative | 42,120 | $0.00 Strike: $6.73 | $0.00 |
DisclosureSEC source: 0001567619-22-014382 · doc1.xml · derivative · entry 9 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 107,880 Underlying: Ordinary Shares · 42,120 shares Expires 2023-03-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: The option was granted on April 1, 2013 and all shares subject to the option were fully vested and exercisable. The option will expire in approximately eight months and be forfeited to the extent it is not exercised on or prior to March 31, 2023. Read SEC document |
| July 20, 2022 Filed Jul 23, 2022 01:37 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 16,984 | $32.73 | $555,921.99 |
DisclosureSEC source: 0001567619-22-014382 · doc1.xml · nonDerivative · entry 3 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,200 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in connection with a court stipulation and proposed order regarding the separation of assets ("Court Order") in anticipation of a potential divorce settlement agreement. F3 · price: The transaction was executed in multiple trades in prices ranging from $32.54 to $33.12, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| July 20, 2022 Filed Jul 23, 2022 01:37 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | SaleOrdinary Shares, par value $0.01 per share | 25,136 | $32.32 | $812,518.69 |
DisclosureSEC source: 0001567619-22-014382 · doc1.xml · nonDerivative · entry 2 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,184 F1 · kind: The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person in connection with a court stipulation and proposed order regarding the separation of assets ("Court Order") in anticipation of a potential divorce settlement agreement. F2 · price: The transaction was executed in multiple trades in prices ranging from $31.54 to $32.535, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| July 20, 2022 Filed Jul 23, 2022 01:37 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Exercise / conversionOrdinary Shares, par value $0.01 per share | 42,120 | $6.73 | $283,467.60 |
DisclosureSEC source: 0001567619-22-014382 · doc1.xml · nonDerivative · entry 1 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,320 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 01, 2022 Filed Aug 19, 2022 17:38 UTC | Rain Oncology Inc. RAIN · Entity 94695 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $2.44 | $0.00 |
DisclosureSEC source: 0000899243-22-029317 · doc4.xml · derivative · entry 1 Nguyen Tran · CIK 0001457013 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-01 F1 · derivative.exercise_date: This option represents a right to purchase a total of 20,000 shares of the Issuer's common stock, which will vest in full on June 1, 2023, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| February 23, 2022 Filed Feb 26, 2022 02:31 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 85,000 | $0.00 Strike: $32.45 | $0.00 |
DisclosureSEC source: 0001140361-22-006891 · form4.xml · derivative · entry 1 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Ordinary Shares · 85,000 shares Expires 2032-02-23 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 23, 2023 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| February 25, 2021 Filed Feb 26, 2021 22:14 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 84,000 | $0.00 Strike: $22.60 | $0.00 |
DisclosureSEC source: 0001567619-21-005091 · doc1.xml · derivative · entry 1 Nguyen Tran · CIK 0001457013 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,000 Underlying: Ordinary Shares · 84,000 shares Expires 2031-02-25 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 25, 2022 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 23:46 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantEmployee Stock Option (Right to Buy) · Derivative | 60,150 | Not disclosed Strike: $22.85 | Not disclosed |
DisclosureSEC source: 0001567619-21-004317 · doc1.xml · derivative · entry 8 Nguyen Tran · CIK 0001457013 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,150 Underlying: Ordinary Shares · 60,150 shares Expires 2028-02-21 F7 · price: On February 12, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 80,000 of the issuer's ordinary shares granted to the reporting person on February 21, 2018. In exchange, the reporting person received a replacement option, for 60,150 ordinary shares, having an exercise price of $22.85 per ordinary share. F8 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 47/48 of the total number of shares subject to the option on the one year anniversary of the date of grant and with respect to 1/48 of the total number of shares subject to the option on February 21, 2022, subject to the reporting person's continued service with the issuer on each such vesting date. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 23:46 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 80,000 | Not disclosed Strike: $33.10 | Not disclosed |
DisclosureSEC source: 0001567619-21-004317 · doc1.xml · derivative · entry 7 Nguyen Tran · CIK 0001457013 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 80,000 shares Expires 2028-02-21 F7 · price: On February 12, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 80,000 of the issuer's ordinary shares granted to the reporting person on February 21, 2018. In exchange, the reporting person received a replacement option, for 60,150 ordinary shares, having an exercise price of $22.85 per ordinary share. F6 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 21, 2019 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the reporting person's continued employment with the issuer on each such vesting date. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 23:46 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantEmployee Stock Option (Right to Buy) · Derivative | 39,062 | Not disclosed Strike: $22.85 | Not disclosed |
DisclosureSEC source: 0001567619-21-004317 · doc1.xml · derivative · entry 6 Nguyen Tran · CIK 0001457013 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,062 Underlying: Ordinary Shares · 39,062 shares Expires 2027-02-22 F5 · price: On February 12, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 75,000 of the issuer's ordinary shares granted to the reporting person on February 22, 2017. In exchange, the reporting person received a replacement option, for 39,062 ordinary shares, having an exercise price of $22.85 per ordinary share. F2 · derivative.exercise_date: The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 23:46 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 75,000 | Not disclosed Strike: $55.00 | Not disclosed |
DisclosureSEC source: 0001567619-21-004317 · doc1.xml · derivative · entry 5 Nguyen Tran · CIK 0001457013 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 75,000 shares Expires 2027-02-22 F5 · price: On February 12, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 75,000 of the issuer's ordinary shares granted to the reporting person on February 22, 2017. In exchange, the reporting person received a replacement option, for 39,062 ordinary shares, having an exercise price of $22.85 per ordinary share. F4 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 22, 2018 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the reporting person's continued employment with the issuer on each such vesting date. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 23:46 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantEmployee Stock Option (Right to Buy) · Derivative | 40,625 | Not disclosed Strike: $22.85 | Not disclosed |
DisclosureSEC source: 0001567619-21-004317 · doc1.xml · derivative · entry 4 Nguyen Tran · CIK 0001457013 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,625 Underlying: Ordinary Shares · 40,625 shares Expires 2026-02-24 F2 · price: The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary. F2 · derivative.exercise_date: The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 23:46 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 65,000 | Not disclosed Strike: $34.61 | Not disclosed |
DisclosureSEC source: 0001567619-21-004317 · doc1.xml · derivative · entry 3 Nguyen Tran · CIK 0001457013 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 65,000 shares Expires 2026-02-24 F3 · price: On February 12, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 65,000 of the issuer's ordinary shares granted to the reporting person on February 24, 2016. In exchange, the reporting person received a replacement option, for 40,625 ordinary shares, having an exercise price of $22.85 per ordinary share. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 23:46 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantEmployee Stock Option (Right to Buy) · Derivative | 50,000 | Not disclosed Strike: $22.85 | Not disclosed |
DisclosureSEC source: 0001567619-21-004317 · doc1.xml · derivative · entry 2 Nguyen Tran · CIK 0001457013 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Ordinary Shares · 50,000 shares Expires 2025-03-11 F1 · price: On February 12, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 55,000 of the issuer's ordinary shares granted to the reporting person on March 11, 2015. In exchange, the reporting person received a replacement option, for 50,000 ordinary shares, having an exercise price of $22.85 per ordinary share. F2 · derivative.exercise_date: The shares subject to the option will vest and become exercisable on the one year anniversary of the date of grant, subject to the reporting person's continued service with the issuer through such one year anniversary. Read SEC document |
| February 12, 2021 Filed Feb 17, 2021 23:46 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative | 55,000 | Not disclosed Strike: $27.81 | Not disclosed |
DisclosureSEC source: 0001567619-21-004317 · doc1.xml · derivative · entry 1 Nguyen Tran · CIK 0001457013 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares · 55,000 shares Expires 2025-03-11 F1 · price: On February 12, 2021, the issuer canceled, pursuant to the issuer's option exchange program, an option for 55,000 of the issuer's ordinary shares granted to the reporting person on March 11, 2015. In exchange, the reporting person received a replacement option, for 50,000 ordinary shares, having an exercise price of $22.85 per ordinary share. Read SEC document |
| April 08, 2020 Filed Feb 14, 2025 23:34 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | OtherOrdinary Shares, par value $0.01 per share | 995 | $0.00 | $0.00 |
DisclosureSEC source: 0000905148-25-000708 · form4.xml · nonDerivative · entry 1 Nguyen Tran · CIK 0001457013 · Chief Strategy Officer and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,205 F1 · kind: Represents shares transferred to the Reporting Person's former spouse in connection with a divorce proceeding. Read SEC document |
| February 25, 2020 Filed Feb 27, 2020 22:14 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (Right to Buy) · Derivative | 105,000 | $0.00 Strike: $12.15 | $0.00 |
DisclosureSEC source: 0001567619-20-005018 · doc1.xml · derivative · entry 2 Nguyen Tran · CIK 0001457013 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Ordinary Shares · 105,000 shares Expires 2030-02-25 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 25, 2021 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| June 11, 2019 Filed Jun 12, 2019 21:50 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0001209191-19-036487 · doc4.xml · derivative · entry 1 Nguyen Tran · CIK 0001457013 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2029-06-11 F1 · derivative.exercise_date: The option vests as to 8.333% of the total shares monthly, beginning on July 11, 2019, with 100% of the total shares vested and exercisable on June 11, 2020, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 21:15 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (right to buy) · Derivative | 95,000 | $0.00 Strike: $13.53 | $0.00 |
DisclosureSEC source: 0000899243-19-005427 · doc4.xml · derivative · entry 2 Nguyen Tran · CIK 0001457013 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Ordinary Shares · 95,000 shares Expires 2029-02-27 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 27, 2020 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| June 21, 2018 Filed Jun 25, 2018 20:32 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (right to buy) · Derivative | 250,000 | $0.00 Strike: $15.04 | $0.00 |
DisclosureSEC source: 0000899243-18-017937 · doc4.xml · derivative · entry 2 Nguyen Tran · CIK 0001457013 · COO and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Ordinary Shares · 250,000 shares Expires 2028-06-21 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on June 21, 2019 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 21:08 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $3.27 | $0.00 |
DisclosureSEC source: 0001209191-18-037787 · doc4.xml · derivative · entry 1 Nguyen Tran · CIK 0001457013 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-06-12 F1 · derivative.exercise_date: The option vests as to 8.333% of the total shares monthly, beginning on July 12, 2018, with 100% of the total shares vested and exercisable on June 12, 2019, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| February 21, 2018 Filed Feb 23, 2018 21:05 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $33.10 | $0.00 |
DisclosureSEC source: 0000899243-18-005298 · doc4.xml · derivative · entry 2 Nguyen Tran · CIK 0001457013 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Ordinary Shares · 80,000 shares Expires 2028-02-21 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 21, 2019 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
| June 13, 2017 Filed Jun 14, 2017 21:30 UTC | Sierra Oncology, Inc. SRRA · Entity 125698 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001209191-17-039875 · doc4.xml · derivative · entry 1 Nguyen Tran · CIK 0001457013 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2027-06-13 F1 · derivative.exercise_date: The option vests as to 8.333% of the total shares monthly, beginning on July 13, 2017, with 100% of the total shares vested and exercisable on June 13, 2018, subject to the reporting person's provision of service to the issuer on each vesting date. Read SEC document |
| March 09, 2017 Filed Mar 9, 2017 21:06 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | PurchaseOrdinary Shares, par value $0.01 per share | 1,000 | $51.32 | $51,317.20 |
DisclosureSEC source: 0000899243-17-006986 · doc4.xml · nonDerivative · entry 1 Nguyen Tran · CIK 0001457013 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,200 F1 · price: The shares were purchased in multiple trades at prices ranging from $51.2492 to $51.46 inclusive. The price reported in Column 4 above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 22, 2017 Filed Feb 24, 2017 21:05 UTC | PROTHENA CORP PUBLIC LTD CO PRTA · Entity 2375 | GrantStock Option (right to buy) · Derivative | 75,000 | $0.00 Strike: $55.00 | $0.00 |
DisclosureSEC source: 0000899243-17-005217 · doc4.xml · derivative · entry 2 Nguyen Tran · CIK 0001457013 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Ordinary Shares · 75,000 shares Expires 2027-02-22 F1 · derivative.exercise_date: The shares subject to the option will vest and become exercisable as to 25% of the total number of shares subject to the option on February 22, 2018 and with respect to 1/48th of the total number of shares subject to the option in successive, equal monthly installments on each monthly anniversary thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.